Using ICR and SCID mice as animal models for smallpox to assess antiviral drug efficacy

The possibility of using immunocompetent ICR mice and immunodeficient SCID mice as model animals for smallpox to assess antiviral drug efficacy was investigated. Clinical signs of the disease did not appear following intranasal (i.n.) challenge of mice with strain Ind-3a of variola virus (VARV), eve...

Full description

Saved in:
Bibliographic Details
Published in:Journal of general virology 2015-09, Vol.96 (9), p.2832-2843
Main Authors: Titova, Ksenya A, Sergeev, Alexander A, Zamedyanskaya, Alena S, Galahova, Darya O, Kabanov, Alexey S, Morozova, Anastasia A, Bulychev, Leonid E, Sergeev, Artemiy A, Glotova, Tanyana I, Shishkina, Larisa N, Taranov, Oleg S, Omigov, Vladimir V, Zavjalov, Evgenii L, Agafonov, Alexander P, Sergeev, Alexander N
Format: Article
Language:English
Subjects:
Animals
Antiviral Agents - administration & dosage
Disease Models, Animal
Drug Evaluation - methods
Female
Humans
Male
Mice
Mice, Inbred ICR
Mice, SCID
Smallpox - drug therapy
Smallpox - pathology
Smallpox - virology
Spleen - pathology
Spleen - virology
Variola virus - drug effects
Variola virus - physiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The possibility of using immunocompetent ICR mice and immunodeficient SCID mice as model animals for smallpox to assess antiviral drug efficacy was investigated. Clinical signs of the disease did not appear following intranasal (i.n.) challenge of mice with strain Ind-3a of variola virus (VARV), even when using the highest possible dose of the virus (5.2 log10 p.f.u.). The 50 % infective doses (ID50) of VARV, estimated by the virus presence or absence in the lungs 3 and 4 days post-infection, were 2.7 ± 0.4 log10 p.f.u. for ICR mice and 3.5 ± 0.7 log10 p.f.u. for SCID mice. After i.n. challenge of ICR and SCID mice with VARV 30 and 50 ID50, respectively, steady reproduction of the virus occurred only in the respiratory tract (lungs and nose). Pathological inflammatory destructive changes were revealed in the respiratory tract and the primary target cells for VARV (macrophages and epithelial cells) in mice, similar to those in humans and cynomolgus macaques. The use of mice to assess antiviral efficacies of NIOCH-14 and ST-246 demonstrated the compliance of results with those described in scientific literature, which opens up the prospect of their use as an animal model for smallpox to develop anti-smallpox drugs intended for humans.
ISSN:0022-1317
1465-2099
DOI:10.1099/vir.0.000216